Codexis, Inc. (CDXS) — Analysis Summary
Codexis, Inc. (CDXS) has a market cap of $204.52M with year-over-year revenue growth of +18.6%. Net margin stands at -62.5%. The stock trades at a P/E ratio of -6.4.
Key Takeaways
- Revenue changed +18.6% year-over-year
- Net margin of -62.5%
- P/E ratio of -6.4
Compared to other companies in the INDUSTRIAL ORGANIC CHEMICALS sector, CDXS posted revenue growth of +18.6% and trades at a P/E of -6.4.
Codexis, Inc. (CDXS)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -37.5% — material operating losses
Net margin at -41.0% — significant losses
The latest filing shows negative free cash flow.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
Sector
INDUSTRIAL ORGANIC CHEMICALS
Employees
146
Headquarters
REDWOOD CITY, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.